Antitumor activity of interleukin-12 against murine bladder cancer

Masatoshi Eto, Mamoru Harada, Koji Tamada, Noriaki Tokuda, Yasuhiro Koikawa, Motonobu Nakamura, Kikuo Nomoto, Seiji Naito

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose: We investigated the antitumor activity of interleukin-12 (IL- 12) against MBT-2, a murine bladder carcinoma, to clarify whether or not IL- 12 is effective against urothelial tumors. Materials and Methods: MBT-2, a murine carcinogen-induced, poorly differentiated transitional cell carcinoma of C3H/He origin, was used. Three or 10 days after the subcutaneous administration of MBT-2 cells, C3H/He mice were injected intraperitoneally with IL-12 five times per wk. for 2 wk. Tumor growth was measured twice weekly. Spleen cells from the C3H/He mice that had rejected MBT-2 after the IL-12 treatment were examined for MBT-2-specific cytolytic T lymphocytes (CTL) activity and cytokine production. Results: Tumor growth and acceptance was obviously suppressed when C3H/He mice were treated with IL-12 from 3 days after the tumor inoculation. In the spleen cells from the C3H/He mice that had rejected MBT-2, MBT-2-specific CTL activity and secretion of IL-2 and interferon (IFN)-γ were clearly detected. However, the established MBT-2 tumor cells were not rejected when C3H/He mice were given IL-12 from 10 days after the tumor inoculation, although the tumor growth was transiently suppressed during the IL-12 treatment. Conclusion: These data demonstrate that IL-12 is considerably effective against murine bladder cancer and suggest the clinical application of IL-12 against human bladder cancer.

Original languageEnglish
Pages (from-to)1549-1552
Number of pages4
JournalJournal of Urology
Volume163
Issue number5
DOIs
Publication statusPublished - Jan 1 2000

Fingerprint

Interleukin-12
Urinary Bladder Neoplasms
Inbred C3H Mouse
Neoplasms
Spleen
Growth
T-Lymphocytes
Transitional Cell Carcinoma
Interleukin-3
Carcinogens
Interleukin-10
Interferons
Interleukin-2
Urinary Bladder
Cytokines
Carcinoma

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Eto, M., Harada, M., Tamada, K., Tokuda, N., Koikawa, Y., Nakamura, M., ... Naito, S. (2000). Antitumor activity of interleukin-12 against murine bladder cancer. Journal of Urology, 163(5), 1549-1552. https://doi.org/10.1016/S0022-5347(05)67677-X

Antitumor activity of interleukin-12 against murine bladder cancer. / Eto, Masatoshi; Harada, Mamoru; Tamada, Koji; Tokuda, Noriaki; Koikawa, Yasuhiro; Nakamura, Motonobu; Nomoto, Kikuo; Naito, Seiji.

In: Journal of Urology, Vol. 163, No. 5, 01.01.2000, p. 1549-1552.

Research output: Contribution to journalArticle

Eto, M, Harada, M, Tamada, K, Tokuda, N, Koikawa, Y, Nakamura, M, Nomoto, K & Naito, S 2000, 'Antitumor activity of interleukin-12 against murine bladder cancer', Journal of Urology, vol. 163, no. 5, pp. 1549-1552. https://doi.org/10.1016/S0022-5347(05)67677-X
Eto M, Harada M, Tamada K, Tokuda N, Koikawa Y, Nakamura M et al. Antitumor activity of interleukin-12 against murine bladder cancer. Journal of Urology. 2000 Jan 1;163(5):1549-1552. https://doi.org/10.1016/S0022-5347(05)67677-X
Eto, Masatoshi ; Harada, Mamoru ; Tamada, Koji ; Tokuda, Noriaki ; Koikawa, Yasuhiro ; Nakamura, Motonobu ; Nomoto, Kikuo ; Naito, Seiji. / Antitumor activity of interleukin-12 against murine bladder cancer. In: Journal of Urology. 2000 ; Vol. 163, No. 5. pp. 1549-1552.
@article{5452672b60dd408892355ec2c3b2eff0,
title = "Antitumor activity of interleukin-12 against murine bladder cancer",
abstract = "Purpose: We investigated the antitumor activity of interleukin-12 (IL- 12) against MBT-2, a murine bladder carcinoma, to clarify whether or not IL- 12 is effective against urothelial tumors. Materials and Methods: MBT-2, a murine carcinogen-induced, poorly differentiated transitional cell carcinoma of C3H/He origin, was used. Three or 10 days after the subcutaneous administration of MBT-2 cells, C3H/He mice were injected intraperitoneally with IL-12 five times per wk. for 2 wk. Tumor growth was measured twice weekly. Spleen cells from the C3H/He mice that had rejected MBT-2 after the IL-12 treatment were examined for MBT-2-specific cytolytic T lymphocytes (CTL) activity and cytokine production. Results: Tumor growth and acceptance was obviously suppressed when C3H/He mice were treated with IL-12 from 3 days after the tumor inoculation. In the spleen cells from the C3H/He mice that had rejected MBT-2, MBT-2-specific CTL activity and secretion of IL-2 and interferon (IFN)-γ were clearly detected. However, the established MBT-2 tumor cells were not rejected when C3H/He mice were given IL-12 from 10 days after the tumor inoculation, although the tumor growth was transiently suppressed during the IL-12 treatment. Conclusion: These data demonstrate that IL-12 is considerably effective against murine bladder cancer and suggest the clinical application of IL-12 against human bladder cancer.",
author = "Masatoshi Eto and Mamoru Harada and Koji Tamada and Noriaki Tokuda and Yasuhiro Koikawa and Motonobu Nakamura and Kikuo Nomoto and Seiji Naito",
year = "2000",
month = "1",
day = "1",
doi = "10.1016/S0022-5347(05)67677-X",
language = "English",
volume = "163",
pages = "1549--1552",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Antitumor activity of interleukin-12 against murine bladder cancer

AU - Eto, Masatoshi

AU - Harada, Mamoru

AU - Tamada, Koji

AU - Tokuda, Noriaki

AU - Koikawa, Yasuhiro

AU - Nakamura, Motonobu

AU - Nomoto, Kikuo

AU - Naito, Seiji

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Purpose: We investigated the antitumor activity of interleukin-12 (IL- 12) against MBT-2, a murine bladder carcinoma, to clarify whether or not IL- 12 is effective against urothelial tumors. Materials and Methods: MBT-2, a murine carcinogen-induced, poorly differentiated transitional cell carcinoma of C3H/He origin, was used. Three or 10 days after the subcutaneous administration of MBT-2 cells, C3H/He mice were injected intraperitoneally with IL-12 five times per wk. for 2 wk. Tumor growth was measured twice weekly. Spleen cells from the C3H/He mice that had rejected MBT-2 after the IL-12 treatment were examined for MBT-2-specific cytolytic T lymphocytes (CTL) activity and cytokine production. Results: Tumor growth and acceptance was obviously suppressed when C3H/He mice were treated with IL-12 from 3 days after the tumor inoculation. In the spleen cells from the C3H/He mice that had rejected MBT-2, MBT-2-specific CTL activity and secretion of IL-2 and interferon (IFN)-γ were clearly detected. However, the established MBT-2 tumor cells were not rejected when C3H/He mice were given IL-12 from 10 days after the tumor inoculation, although the tumor growth was transiently suppressed during the IL-12 treatment. Conclusion: These data demonstrate that IL-12 is considerably effective against murine bladder cancer and suggest the clinical application of IL-12 against human bladder cancer.

AB - Purpose: We investigated the antitumor activity of interleukin-12 (IL- 12) against MBT-2, a murine bladder carcinoma, to clarify whether or not IL- 12 is effective against urothelial tumors. Materials and Methods: MBT-2, a murine carcinogen-induced, poorly differentiated transitional cell carcinoma of C3H/He origin, was used. Three or 10 days after the subcutaneous administration of MBT-2 cells, C3H/He mice were injected intraperitoneally with IL-12 five times per wk. for 2 wk. Tumor growth was measured twice weekly. Spleen cells from the C3H/He mice that had rejected MBT-2 after the IL-12 treatment were examined for MBT-2-specific cytolytic T lymphocytes (CTL) activity and cytokine production. Results: Tumor growth and acceptance was obviously suppressed when C3H/He mice were treated with IL-12 from 3 days after the tumor inoculation. In the spleen cells from the C3H/He mice that had rejected MBT-2, MBT-2-specific CTL activity and secretion of IL-2 and interferon (IFN)-γ were clearly detected. However, the established MBT-2 tumor cells were not rejected when C3H/He mice were given IL-12 from 10 days after the tumor inoculation, although the tumor growth was transiently suppressed during the IL-12 treatment. Conclusion: These data demonstrate that IL-12 is considerably effective against murine bladder cancer and suggest the clinical application of IL-12 against human bladder cancer.

UR - http://www.scopus.com/inward/record.url?scp=0034051006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034051006&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(05)67677-X

DO - 10.1016/S0022-5347(05)67677-X

M3 - Article

C2 - 10751886

AN - SCOPUS:0034051006

VL - 163

SP - 1549

EP - 1552

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -